Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A closer look at 3DNA
June 2017
SHARING OPTIONS:

HATFIELD, Pa.—Genisphere LLC and the University of Maryland, through Dr. Silvia Muro, have partnered under a collaborative and sponsored research agreement to study the pharmacokinetics and pharmacodynamics of different 3DNA designs and formulations after in-vivo administration. The partners will also seek to target vasculature diseases and inflammatory responses, demonstrate methods of endocytosis and study how 3DNA crosses the blood-brain barrier. Genisphere's 3DNA nanotechnology is a 3D structure comprised entirely of DNA, and the company notes that “Using DNA as a biomaterial for manufacturing offers several inherent advantages including scalability, stability and precise control of the final size and shape of 3DNA. The multivalency of 3DNA allows finely tuned targeting capabilities and high capacity for a variety of payloads. The modular and flexible properties of 3DNA make it easy for Genisphere to quickly develop reagents for a variety of applications.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.